CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: Usefulness of in vitro apoptosis in leukemic cells

Authors
Mori, M Hatake, K Tanaka, M Takatoku, M Matsumoto, Y Uchida, M Kametaka, N Nagai, T Terui, Y Tomizuka, H Muroi, K Ozawa, K
Citation
M. Mori et al., CAM-cytarabine, aclarubicin plus macrophage colony-stimulating factor in the treatment of acute myelogenous leukemia with trilineage dysplasia: Usefulness of in vitro apoptosis in leukemic cells, LEUK LYMPH, 42(3), 2001, pp. 387-391
Citations number
16
Categorie Soggetti
Hematology,"Onconogenesis & Cancer Research
Journal title
LEUKEMIA & LYMPHOMA
ISSN journal
10428194 → ACNP
Volume
42
Issue
3
Year of publication
2001
Pages
387 - 391
Database
ISI
SICI code
1042-8194(200107)42:3<387:CAPMCF>2.0.ZU;2-R
Abstract
A 67-year-old woman was treated for acute myelogenous leukemia with triline age dysplasia (AML-TLD) by combination chemotherapy with cytarabine, aclaru bicin plus macrophage colony-stimulating factor (M-CSF) (referred to as CAM therapy). Complete remission was achieved after two courses of CAM therapy . After coculture of her bone marrow mononuclear cells with M-CSF in vitro, differentiation of leukemic cells into macrophages with apoptotis was obse rved. This case confirms an earlier report that an effect of M-CSF inducibl e by differentiation with apoptotic phenomena, against human leukemic cells was shown both in vitro and in vivo when achieving complete remission.